Clinical trial NCT00667628: Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of TAC-101 in Combination With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Advanced Hepatocellular Carcinoma
Lead sponsor: Taiho Oncology, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Quintiles, Inc.
First posted: 2008-04-28
Enrollment: 54
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether TAC-101 combined with Transcatheter Arterial Chemoembolization (TACE) is more effective than TACE alone in slowing tumor activity in patients with advanced hepatocellular carcinoma. The study is also looking at the safety of TAC-101 in combination with TACE.

Detailed description: Advanced metastatic hepatocellular carcinoma (HCC) is not treatable by surgical approaches or locoregional therapies such as hepatic artery hemoembolization or radiofrequency ablation (RFA) which are effective in controlling localized tumors. Transcatheter arterial chemoembolization (TACE) is the most commonly performed procedure in the treatment of unresectable liver tumors for selected patients. The TACE procedure delivers highly concentrated drugs to the tumor itself and arrests blood flow. Most patients will have intrahepatic recurrence of their tumors following TACE. Studies of TAC-101, a synthetic retinoid, indicate that although TAC-101 may not induce tumor regression, it appears to have a stabilizing effect, prolonging survival over what was expected historically. This study is designed as a randomized, double-blind, placebo-controlled, parallel-group, phase 2 study in patients with advanced HCC who have undergone a TACE procedure, which will be conducted at multiple sites in Japan, to determine if administration of TAC-101 will enhance the benefits of the TACE procedure.

Eligibility criteria: Inclusion Criteria:

- A patient must meet all of the following inclusion criteria to be eligible for enrollment in this study and before undergoing the first TACE procedure of this study:

1. Has an HCC diagnosis by histology or by the following non-invasive criteria observed either at enrollment or in the past.

   * One imaging technique (CT scan or magnetic resonance imaging \[MRI\] both with unenhanced plus hepatic arterial phase and portal venous phases) showing characteristic features in a focal lesion \> 20 mm with arterial vascularization.
   * Two dynamic imaging techniques (CT scan, MRI with unenhanced plus hepatic arterial phase and portal venous phases) showing characteristic features coincidentally in a focal lesion 10-20 mm with arterial vascularization.
2. Is TACE naïve or has received the most recent TACE procedure at least 120 days before signing ICF.
3. Eligible to receive TACE and being scheduled to receive TACE.
4. Must be ≥ 20 years of age.
5. Is not amenable to treatment with curative surgery, transplant, or percutaneous ablation, including RFA, percutaneous ethanol injection therapy (PEIT) and percutaneous microwave coagulation therapy (PMCT).
6. Must have lesions in the liver that are confirmed nodular type with demonstrated substantial hypervascularity by CT scan or MRI both with unenhanced plus hepatic arterial phase and portal venous phases performed prior to first TACE in this study with the following tumor features:

   * If there are ≥ 4 intrahepatic lesions, all lesions can be \< 30 mm. or, regardless of the number of lesions, the longest diameter of at least one intrahepatic lesion is ≥ 30 mm).
   * No vascular invasion in main trunk and first order branch of portal vein.
   * No extrahepatic tumor spread. The absence of extrahepatic abdominal tumors must be confirmed.
7. Has adequate organ function as defined by the following criteria: White blood cell (WBC) count \> 3,000/mm3; Platelet count \> 60,000/mm3; Hemoglobin \> 8.0 grams (g)/deciliter (dL); Aspartate transaminase (AST) \< 5 x upper limit of normal (ULN); Alanine transaminase (ALT) \< 5 x ULN; Total bilirubin \< 2.0 mg/dL; Albumin ≥ 2.8 g/dL; Serum creatinine ≤ 1.5 mg/dL; International normalized ratio (INR) ≤ 2.0; Triglyceride ≤ 2.5 x ULN.
8. Must have a Child-Pugh classification of ≤ 8.
9. Must have a Cancer of the Liver Italian Program (CLIP)60 score of 0, 1, 2 or 3 (Appendix B).
10. Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
11. Must be willing and able to comply with schedule visits, treatment plans, laboratory tests, and other study procedures.
12. Must provide written informed consent prior to the implementation of any study assessment or procedures.

Exclusion Criteria:

* Patients will be excluded from participation in the study if any of the following conditions are observed before undergoing the first TACE procedure:

  1. Patient has longest diameter of intrahepatic lesion ≥ 100 mm.
  2. Patient has only infiltration type of HCC.
  3. Patient has extrahepatic metastasis of HCC including regional lymph node metastases (including in lymph nodes and organs).
  4. Patient had systemic chemotherapy (eg, sorafenib, doxorubicin), immunotherapy, or biologic therapy or radiotherapy for HCC, or treatment with TAC-101.
  5. Patient received treatment with any of the following within the specified time frame: Any major surgical procedure within 28 days prior to signing the ICF; Any transfusion, treatment with blood component preparation, albumin preparation, and granulocyte colony stimulating factor (G-CSF) within 14 days prior to signing the ICF; Any local therapy such as alcohol injection, radiofrequency/ultrasound ablation, intraarterial chemotherapy (transcatheter arterial injection) for HCC performed within 28 days prior to signing the ICF; Any investigational agent within 28 days prior to signing the ICF.
  6. Patient has ascites, pleural effusions or pericardial fluid refractory to diuretic therapy.
  7. Patient has clinical symptoms of hepatic encephalopathy.
  8. Patient has active or uncontrolled clinically serious infection excluding chronic hepatitis.
  9. Patient has a history of gastrointestinal (GI) bleeding in last 3 months.
  10. Patient has previous or concurrent malignancy except for in situ carcinoma of the cervix, or other solid tumor treated curatively and without evidence of recurrence for at least 3 years prior to the study.
  11. Patient has uncontrolled metabolic disorders or other nonmalignant organ or systemic diseases or secondary effects of cancer that induce a high medical risk and/or make assessment of survival uncertain.
  12. Patient has any history of deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (MI), cerebrovascular accident (CVA), transient ischemic attack (TIA), unstable angina pectoris, or any other significant thromboembolic event (TE) during the last 3 years.
  13. Patient has clinically significant electrocardiogram (ECG) abnormality.
  14. Patient has GI disease resulting in an inability to take oral medication.
  15. Patient has known allergy or hypersensitivity to TAC-101, doxorubicin, epirubicin, other anthracyclines, anthracenediones or any of the components used in the study drug formulations.
  16. Patient has known hypersensitivity to iodinated contrast medium.
  17. Patient is receiving therapeutic regimens of anticoagulants. However, use of low dose anticoagulants for prophylactic care of indwelling venous access device is permitted.
  18. Patient is taking medication known or suspected to predispose patient to an increased risk of VTE (eg, oral contraceptives, hormone replacement therapy, megestrol acetate).
  19. Patient is taking azoles or tetracyclines, because of the potential for drug interactions.
  20. Women who intend to become pregnant or are pregnant or lactating and men able to procreate that refuse to use a highly effective method of birth control during treatment with study medication and up to 6 months thereafter.

Primary outcomes:
measure: Time to Appearance of New Lesions (TTNL)
timeFrame: From randomization (within 14 days prior to first TACE) assessed every 9 weeks after first TACE to date of appearance of a new lesion or until cut-off date (22-Dec-2009) (up to approximately 20 months)
Secondary outcomes:
measure: Overall Survival (OS)
timeFrame: From randomization (within 14 days prior to first TACE) assessed every 9 weeks after first TACE until cut-off date of 22 Dec 2009 (up to approximately 20 months)
measure: Progression-Free Survival (PFS)
timeFrame: From randomization (within 14 days prior to first TACE) assessed every 9 weeks after first TACE until cut-off date of 22 Dec 2009 (up to approximately 20 months)
measure: Objective Tumor Response Rate (ORR)
timeFrame: From randomization (within 14 days prior to first TACE) assessed every 9 weeks after first TACE until cut-off date of 22 Dec 2009 (up to approximately 20 months)
measure: Change From Baseline in Plasma Levels of Tumor Marker Alpha-fetoprotein (AFP)
timeFrame: Baseline, End of treatment (last dose of study medication, i.e., approximately 7 months)
measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
timeFrame: From first dose of study drug up to 30 days after last dose of study drug or until the start of new anti-tumor therapy, whichever was earlier (up to approximately 8.5 months)
Other outcomes:
Locations:
city: Nagoya
country: Japan
facility: Aichi Cancer Center Hospital
state: Aichi
city: Matsuyama
country: Japan
facility: National hospital organization Shikoku Cancer Center
state: Ehime
city: Jonan-ku
country: Japan
facility: Fukuoka University Hospital
state: Fukuoka
city: Kurume
country: Japan
facility: Kurume University Hospital
state: Fukuoka
city: Oogaki
country: Japan
facility: Ogaki Municipal Hospital
state: Gifu
city: Fukuyama
country: Japan
facility: Fukuyama City Hospital
state: Hiroshima
city: Asahikawa
country: Japan
facility: Asahikawa-Kosei General Hospital
state: Hokkaido
city: Sapporo
country: Japan
facility: Hokkaido University Hospital
state: Hokkaido
city: Hishinomiya
country: Japan
facility: The Hospital of Hyogo College of Medicine
state: Hyogo
city: Kanazawa
country: Japan
facility: Kanazawa University Hospital
state: Ishikawa
city: Morioka
country: Japan
facility: Iwate Medical University Hospital
state: Iwate
city: Yokohama
country: Japan
facility: Yokohama City University Medical Center
state: Kanagawa
city: Tsu
country: Japan
facility: Mie University Hospital
state: Mie
city: Kashihara
country: Japan
facility: Nara Medical University Hospital
state: Nara
city: Shikata-cho
country: Japan
facility: Okayama University Hospital
state: Okayama
city: Abeno-ku
country: Japan
facility: Osaka City University Hospital
state: Osaka
city: Higashinari-ku
country: Japan
facility: Osaka medical Center for Cancer and Cardiovascular Diseases
state: Osaka
city: Miyakojima-ku
country: Japan
facility: Osaka City General Hospital
state: Osaka
city: Moriguchi
country: Japan
facility: Kansai Medical Univesity Takii Hospital
state: Osaka
city: Osaka-sayama
country: Japan
facility: Kinki University Hospital
state: Osaka
city: Tennoji-ku
country: Japan
facility: Osaka Red Cross Hospital
state: Osaka
city: Sunto-gun
country: Japan
facility: Shizuoka Cancer Center Hospital
state: Shizuoka
city: Bunkyo-ku
country: Japan
facility: The University of Tokyo Hospital
state: Tokyo
city: Chiyoda-ku
country: Japan
facility: Tochigi Cancer Center
state: Tokyo
city: Chiyoda
country: Japan
facility: Kyoundo Hospital
state: Tokyo
city: Chuo-ku
country: Japan
facility: National Cancer Center Hospital
state: Tokyo
city: Kimidera
country: Japan
facility: Wakayama Medical University Hospital
state: Wakayama
city: Kochi
country: Japan
facility: Kochi Health Science Center
city: Kumamoto
country: Japan
facility: Kumamoto University Hospital
Study officials:
affiliation: Taiho Oncology, Inc.
name: Taiho Central, MD
role: STUDY_DIRECTOR
References: